renal-cell carcinoma (advanced)

     

Select            
Trial Studied trt Control trt patientstagsROB Trial result

angiogenesis inhibitors

bevacizumab
CALGB 90206, 2010         bevacizumab plus interferon alfainterferon alphasuggesting
AVOREN, 2007         bevacizumab plus interferon alfainterferon alphasuggesting
Yang, 2003       bevacizumabplaceboExploratory -

immune checkpoint inhibition

nivolumab
Chekmate 025 (Motzer), 2015      NCTnivolumabeverolimus2LRisk of bias suggesting
CheckMate-214, 2017      NCTnivolumab + ipilimumabsunitinib1LRisk of bias conclusive

mTOR inhibitor

everolimus
RECORD-1, 2008      NCTeverolimusplacebosuggesting
RECORD 3, 2014      NCTeverolimussunitinib -
temsirolimus
ARCC (Hudes) temsirolimus alone, 2007      NCTtemsirolimusinterferon alphasuggesting
INTORSECT, 2014      NCTtemsirolimussorafenibnegative

multi target TKI

not classified
Disruptor-1   BNC105P + everolimuseverolimus -
apitolisib
Powles, 2014   apitolisibeverolimus -
axitinib
AXIS (Rini), 2011      NCTaxitinibsorafenibsuggesting
Qin, 2012   axitinibsorafenib -
cabozantinib
METEOR, 2015    NCTcabozantinibeverolimus after VEGFR-targeted therapy failure 2nd line Risk of bias suggesting
CABOSUN, 2017      NCTcabozantinibsunitinibfirst-line therapy in patients with intermediate- or poor-risk 1st line Exploratory suggesting
dovitinib
GOLD      NCTdovitinibsorafenibRisk of bias negative
pazopanib
Sternberg, 2010     pazopanibplaceboLow risk of bias suggesting
VEG105192, 2010        NCTpazopanibplacebosuggesting
COMPARZ, 2013      NCTpazopanibsunitinibnegative
sorafenib
Escudier, 2009     sorafenibinterferon alphaExploratory negative
TARGET, 2007          NCTsorafenibplaceboLow risk of bias suggesting
Ratain, 2006     sorafenibplaceboExploratory -
sunitinib
Motzer, 2007          NCTsunitinibinterferon alphasuggesting
SWITCH      NCTsunitinibsorafenib -
tivozanib
TIVO-1, 2013      NCTtivozanibsorafenibsuggesting